356 related articles for article (PubMed ID: 12673686)
1. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
2. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.
Xiang W; Wimberger P; Dreier T; Diebold J; Mayr D; Baeuerle PA; Kimmig R
J Cancer Res Clin Oncol; 2003 Jun; 129(6):341-8. PubMed ID: 12819960
[TBL] [Abstract][Full Text] [Related]
4. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
5. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
[TBL] [Abstract][Full Text] [Related]
6. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
7. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
8. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
9. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
[TBL] [Abstract][Full Text] [Related]
10. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
11. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H
Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189
[TBL] [Abstract][Full Text] [Related]
12. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
13. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
[TBL] [Abstract][Full Text] [Related]
14. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
[TBL] [Abstract][Full Text] [Related]
15. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
Riesenberg R; Buchner A; Pohla H; Lindhofer H
J Histochem Cytochem; 2001 Jul; 49(7):911-7. PubMed ID: 11410615
[TBL] [Abstract][Full Text] [Related]
16. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28.
Kroesen BJ; Bakker A; van Lier RA; The HT; de Leij L
Cancer Res; 1995 Oct; 55(19):4409-15. PubMed ID: 7545540
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
19. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110.
Witthauer J; Schlereth B; Brischwein K; Winter H; Funke I; Jauch KW; Baeuerle P; Mayer B
Breast Cancer Res Treat; 2009 Oct; 117(3):471-81. PubMed ID: 18819003
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
